Cookie preferences

Essential storage keeps iPulse AI reliable. Optional analytics and LinkedIn ad measurement stay off unless you accept. Privacy Policy

Skip to main content
Pfizer logo
PFE.NYSE
Pfizer
Health Care · Pharmaceuticals
Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.MoreShow less
HQ: United StatesListed: United States

Profile & Fundamentals

Pfizer (PFE.NYSE) Profile & Fundamentals

Review Pfizer reported earnings, valuation, balance sheet and ownership, with source tables and separate AI assessments.

Interactive annual chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Company and Market Context

Pfizer: Company Profile & Ownership

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE.NYSE

Company profile record

Pfizer Inc

Common Stock · Health Care · Pharmaceuticals

Official website

Company

Company / asset
Pfizer Inc
Security type
Common Stock
Sector
Health Care
Industry
Pharmaceuticals
HQ
🇺🇸 United States
Head office
66 Hudson Boulevard East, New York, NY, United States, 10001-2192

Leadership & scale

Chief executive
Dr. Albert Bourla D.V.M., Ph.D.
CEO year born
1962
Full-time employees
75K
Fiscal year end
December
IPO date
1942-06-22

Fundamentals snapshot

Updated 2026-11-08
Market Cap
USD 168.8B
P/E
41.9x
Revenue (Q3 26)
USD 16.6B
Profit (Q3 26)
USD 3.2B
Dividend Yield
4.1%
Revenue (FY 25)
USD 62.6B
Shares in public float
5.7B
Insider ownership
0.1%

Reporting & identifiers

Symbol
PFE.NYSE
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US7170811035
Asset ID
equity_6450e9e7-4c57-5c72-97d1-057751df8e53

Pfizer: Ownership

Shares Outstanding

Latest: 5.8B | Max: 6.1B | Min: 5.6B

Shares Outstanding
7.6B5.7B3.8B1.9B0.00
5.8B
'17
'19
'21
'23
'25
'26

Latest reported ownership snapshot

Float Shares

98.98%

5.7B latest reported shares

Insider Ownership

0.10%

Latest reported insider stake

Short Float

0.02%

Latest reported short interest / float

Top Holders

Top 5 concentration: 27.01%
BlackRock Inc
institution
Filed 2026-06-30 • Change +31.4M (+6.30%)
9.29%(529.7M shares)
Vanguard Capital Management, LLC
institution
Filed 2026-06-30 • Change +2.7M (+0.74%)
6.53%(372.1M shares)
State Street Corp
institution
Filed 2026-06-30 • Change +5.5M (+1.82%)
5.39%(307.1M shares)
Vanguard MStar Total Stk Mkt Idx Invest
fund
Filed 2026-09-30 • Change -216.8K (-0.12%)
3.17%(180.9M shares)
Vanguard 500 Index Investor
fund
Filed 2026-09-30 • Change -1.7M (-1.15%)
2.63%(149.7M shares)
Geode Capital Management, LLC
institution
Filed 2026-06-30 • Change +1.7M (+1.28%)
2.37%(135.3M shares)
Vanguard Portfolio Management, LLC
institution
Filed 2026-06-30 • Change +2.5M (+2.14%)
2.09%(119.2M shares)
Source tablesView ownership tables

Shares Outstanding

Annual reported shares outstanding; up to 10 reporting dates.

Scroll the table to see every column.

Shares outstanding — reported values
Reporting dateShares outstanding
2017-01-016,064,000,000
2018-01-015,788,000,000
2019-01-015,631,000,000
2020-01-015,662,000,000
2021-01-015,768,000,000
2022-01-015,743,000,000
2023-01-015,647,000,000
2024-01-015,703,000,000
2025-01-015,686,000,000
2026-01-015,751,000,000

Top Holders

Available reported ownership records.

Scroll the table to see every column.

Largest reported holders
HolderSharesOwnershipReported date
BlackRock Inc529,670,4339.29%2026-06-30
Vanguard Capital Management, LLC372,149,8526.53%2026-06-30
State Street Corp307,090,8975.39%2026-06-30
Vanguard MStar Total Stk Mkt Idx Invest180,931,3373.17%2026-09-30
Vanguard 500 Index Investor149,689,3912.63%2026-09-30
Geode Capital Management, LLC135,275,7822.37%2026-06-30
Vanguard Portfolio Management, LLC119,235,0302.09%2026-06-30
Fisher Asset Management, LLC109,067,2911.91%2026-06-30
Morgan Stanley - Brokerage Accounts96,345,4521.69%2026-06-30
iShares Core S&P 500 ETF76,002,2621.33%2026-10-30
Fidelity 500 Index74,072,7171.3%2026-09-30
State Street® SPDR® S&P 500® ETF69,540,8411.22%2026-10-30
NORGES BANK61,505,5861.08%2026-06-30
Northern Trust Corp59,084,5731.04%2026-06-30
Bank of New York Mellon Corp57,879,5461.02%2026-06-30

Pfizer: Earnings, Profitability & Valuation

Latest Financials Filed On

Earnings & Revenue

Earnings and Revenue Trajectory

AI Review

AI review as of Sep 20, 2026. Newer financial records are available: Financial statements filed Nov 3, 2026. This review has not been updated for those records.

Pfizer's financial story is one of operational stabilization following the post-pandemic vaccine unwind. Headline revenue stabilized near sixty-three point seven billion dollars for the trailing twelve months through mid-2026, demonstrating that non-COVID medicines are growing steadily. Although accounting results showed a net loss in the second quarter of 2026 due to a four-point-three-billion-dollar non-cash clinical trial impairment, core operating income remained resilient at nearly sixteen billion dollars. This gap reveals that actual cash generation is significantly healthier than reported net losses suggest. Trailing free cash flow reached eleven billion dollars, providing crucial liquidity to self-fund operations and protect shareholder distributions as legacy patent expirations approach.

Revenue, Net Income, and Free Cash Flow

Latest: USD 62.6B | Max: USD 101.2B | Min: USD 2.1B

RevenueFree Cash FlowNet Income
USD 127.5BUSD 95.6BUSD 63.7BUSD 31.9BUSD 0.00
62.6B
9.1B
7.8B
'16
'18
'20
'22
'24
'25

Valuation

P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.

Latest: 18x

88x66x43x20x0x
15x
76x
18x
'21'23'25

Profitability & Margins

Margins and Operating Efficiency

AI Review

AI review as of Sep 20, 2026. Newer financial records are available: Financial statements filed Nov 3, 2026. This review has not been updated for those records.

Profitability is rebounding after absorbing pandemic-related disruptions. Gross margins expanded to seventy point three percent in fiscal 2025, recovering from fifty point nine percent in 2023 as low-margin vaccine inventories cleared and sales shifted toward high-margin cancer biologics. Operating margins stabilized near twenty-five percent, directly supported by ongoing corporate cost-reduction programs. This margin pattern demonstrates underlying pricing power across specialized treatments. Enterprise restructuring initiatives targeting billions in cumulative operational savings provide vital operating leverage. This disciplined cost containment creates a durable cushion that protects profitability even as mature small-molecule drugs encounter generic price competition.

Profitability Margins

Latest: 74.3% | Max: 80.3% | Min: 3.6%

Gross MarginOperating MarginNet Margin
101.2%75.9%50.6%25.3%0.0%
74.3%
27.8%
12.4%
'16
'18
'20
'22
'24
'25

Latest Profitability Ratios as of 2025-12-31

Gross Margin

74.3%

Gross profit / revenue

Operating Margin

27.8%

Operating income / revenue

Net Margin

12.4%

Net income / revenue

FCF Margin

14.5%

Free cash flow / revenue

Source tablesView earnings, profitability & valuation tables

Revenue, Net Income, and Free Cash Flow

Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.

Scroll the table to see every column.

Annual earnings and cash flow
Period endRevenue (USD)Net income (USD)Free cash flow (USD)
2016-12-3152,824,000,0007,215,000,00013,902,000,000
2017-12-3152,546,000,00021,308,000,00014,253,000,000
2018-12-3140,825,000,00011,153,000,00013,631,000,000
2019-12-3140,905,000,00016,026,000,0009,994,000,000
2020-12-3141,651,000,0009,159,000,00011,612,000,000
2021-12-3181,288,000,00021,979,000,00029,869,000,000
2022-12-31101,175,000,00031,372,000,00026,031,000,000
2023-12-3159,554,000,0002,119,000,0004,793,000,000
2024-12-3163,627,000,0008,031,000,0009,835,000,000
2025-12-3162,579,000,0007,771,000,0009,076,000,000

Published P/E Ratio

Published valuation snapshots retain each observation's earnings basis.

Scroll the table to see every column.

Published valuation snapshots
Period endP/E (times earnings)Earnings basis
2025-12-3118.2Trailing four quarters
2024-12-3118.9Trailing four quarters
2023-12-3176.3Trailing four quarters
2022-12-319.4Annual net income
2021-12-3115.4Annual net income

Profitability Margins

Matching annual reporting dates. Values are percentages.

Scroll the table to see every column.

Annual profitability margins
Period endGross margin (%)Operating margin (%)Net margin (%)Free cash flow margin (%)
2016-12-3176.6725.9513.6626.32
2017-12-3178.6326.7840.5527.12
2018-12-3177.9916.4827.3233.39
2019-12-3180.3117.8739.1824.43
2020-12-3179.6321.221.9927.88
2021-12-3162.0824.8927.0436.74
2022-12-3166.0537.6731.0125.73
2023-12-3158.17.423.568.05
2024-12-3171.9423.4812.6215.46
2025-12-3174.3327.8212.4214.5

Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Snapshot retrieved 2026-11-10.

Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.